Scot W Ebbinghaus

Title: Scot W Ebbinghaus: Innovator in Cancer Therapy

Introduction

Scot W Ebbinghaus is a notable inventor based in North Wales, PA (US). He has made significant contributions to the field of cancer treatment through his innovative patent. His work focuses on combination therapies that target specific pathways involved in cancer progression.

Latest Patents

Ebbinghaus holds a patent for "Combination therapies for cancer." This novel combination includes a B-Raf inhibitor, specifically N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof. Additionally, it features the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, along with a PD-1 antagonist. This patent outlines pharmaceutical compositions and methods for using these combinations in treating conditions where MEK and/or B-Raf inhibition and immune modulation through PD-1 are beneficial, particularly in cancer.

Career Highlights

Throughout his career, Scot W Ebbinghaus has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Novartis AG. His experience in these organizations has contributed to his expertise in developing innovative therapies for cancer treatment.

Collaborations

Ebbinghaus has collaborated with notable colleagues, including Elaine M Pinheiro and Venkataraman Sriram. These partnerships have likely enhanced his research and development efforts in the field of oncology.

Conclusion

Scot W Ebbinghaus is a distinguished inventor whose work in combination therapies for cancer represents a significant advancement in medical science. His innovative approaches and collaborations continue to influence the landscape of cancer treatment.